slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 33,181-33,210
Pages 1,935
Rows per page 30
Slide function
33,181-33,210 of 58,039
15
The chart highlights two key conversion rates: ~53% for Unlevered Free Cash Flow and ~12% for Levered Free Cash Flow (Pre-M&A).Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
17
Includes detailed footnotes regarding debt terms and equity instruments.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
21
This is a standard financial disclosure slide for non-GAAP metrics.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
22
This is a standard financial disclosure table showing historical adjustments to GAAP net income.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
23
This is part 4 of 6 of a non-GAAP reconciliation series.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
24
This is a standard financial disclosure slide for non-GAAP metrics.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
06
Red boxes highlight key clinical history metrics: time since diagnosis, splenectomy history, prior therapies, and concurrent therapy usage.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Agitation1 hit
07
The slide uses a hierarchical testing procedure for statistical significance.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Solution1 hit
08
The chart includes error bars and a table of participant counts at the bottom.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Before-After Comparison1 hit
09
The slide uses a stacked bar chart to visualize the response rates and a table to detail specific IWG criteria outcomes.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Comparative Analysis1 hit
10
The chart uses a back-to-back bar structure to visualize the distribution of disease control duration.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
11
The chart displays point estimates and 95% confidence intervals for the treatment effect across multiple clinical and demographic categories.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Loop · Mece Breakdown1 hit
12
The chart displays a significant, sustained reduction in IgG levels for the treatment group compared to placebo.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
13
The table compares adverse events (TEAEs) and specific common events between treatment and placebo groups.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
12
Includes a table of patients at risk below the x-axis and a summary table of PFS events, median PFS, and hazard ratio.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
13
Includes a table of PFS events, median PFS, and adjusted hazard ratio (HR) alongside the survival plot and risk table.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
14
Includes a risk table and summary statistics table (Median PFS, HR).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
15
Includes risk tables and hazard ratios (HR) with 95% confidence intervals.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
16
Includes a forest plot for subgroup analysis and a summary table for prior treatments.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
17
The slide uses a mirrored bar chart to compare adverse event frequencies by grade, alongside a summary table of clinical safety outcomes.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
21
The slide presents clinical trial baseline data, likely for a breast cancer study given the markers (ER+, PgR+, ESR1m, CDK4/6i).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a standard Kaplan-Meier survival analysis framework common in oncology clinical trials.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
23
Clinical trial data visualization showing hazard ratios and median PFS.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
24
Clinical trial data visualization showing progression-free survival (PFS) curves with associated hazard ratios and event counts.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
25
The slide uses a split-panel design to compare two patient cohorts (ESR1m detectable vs not detectable).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
26
Clinical trial data visualization showing hazard ratios and median PFS.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
27
The table compares adverse event (AE) frequencies, treatment-related AEs (TRAEs), and dose modifications.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
28
The table lists 15 specific adverse events plus 'Any AE' across 4 cohorts, with two columns per cohort (All grades, Grade >=3).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
31
Includes Kaplan-Meier survival curve and key efficacy metrics.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
37
The slide uses a stacked bar chart to show market share evolution over three quarters and bulleted lists to summarize clinical trial outcomes.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit